<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700658</url>
  </required_header>
  <id_info>
    <org_study_id>TV46046-WH-10147</org_study_id>
    <nct_id>NCT03700658</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous Administration of TV46046</brief_title>
  <official_title>A Randomized Crossover Study to Evaluate Local Tolerability Following Subcutaneous Administration of TV-46046</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the local tolerability associated with the
      subcutaneous administration of TV-46046, and inform next steps of the TV-46046 development
      program.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 14, 2018</start_date>
  <completion_date type="Anticipated">October 24, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 17, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The study will be partially blinded due to differences in appearance and volume of the treatments. Designated unblinded study staff will conduct randomization procedures. The staff preparing and administering injections will also be unblinded to treatment sequence but will be trained to shield the syringe prior to and at the time of injection from view of the subject and study staff assessing ISRs.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Injection Site Reaction excluding injection site pain</measure>
    <time_frame>Days 0 (immediately after and 1 hour after the injection), 1, 3, 7 and 14, at Months 3 and 6, and at additional visits, if indicated</time_frame>
    <description>Assessed by self-reports and direct observation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Injection Site Pain</measure>
    <time_frame>Day 0 (immediately after and 1 hour after the injection).</time_frame>
    <description>Assessed by Numerical Rating Scale (NRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's perception of pain</measure>
    <time_frame>Day 0 (1 hour after the last injection)</time_frame>
    <description>Assessed by an overall ranking of the 4 study injections from least [1] to most [4] painful</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AEs</measure>
    <time_frame>Months 1, 2, 3, 4, 5, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Concomitant Medications</measure>
    <time_frame>Months 1, 2, 3, 4, 5, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Day 0 &amp; Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulse respiration rate</measure>
    <time_frame>Day 0 &amp; Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in temperature</measure>
    <time_frame>Day 0 &amp; Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Day 0 &amp; Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>TV-46046 - 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One of 24 sequences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TV-46046 - 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One of 24 sequences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medroxyprogesterone acetate injectable suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One of 24 sequences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TV-46046 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One of 24 sequences</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46046 - 1</intervention_name>
    <description>120 mg/0.3 mL</description>
    <arm_group_label>TV-46046 - 1</arm_group_label>
    <arm_group_label>TV-46046 - 2</arm_group_label>
    <arm_group_label>TV-46046 Placebo</arm_group_label>
    <arm_group_label>medroxyprogesterone acetate injectable suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46046 - 2</intervention_name>
    <description>60 mg/0.3 mL of 1:1 saline-diluted TV-46046</description>
    <arm_group_label>TV-46046 - 1</arm_group_label>
    <arm_group_label>TV-46046 - 2</arm_group_label>
    <arm_group_label>TV-46046 Placebo</arm_group_label>
    <arm_group_label>medroxyprogesterone acetate injectable suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medroxyprogesterone acetate injectable suspension</intervention_name>
    <description>104 mg/0.65 mL (injectable suspension)</description>
    <arm_group_label>TV-46046 - 1</arm_group_label>
    <arm_group_label>TV-46046 - 2</arm_group_label>
    <arm_group_label>TV-46046 Placebo</arm_group_label>
    <arm_group_label>medroxyprogesterone acetate injectable suspension</arm_group_label>
    <other_name>Depo-subQ 104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46046 Placebo</intervention_name>
    <description>0.3 mL</description>
    <arm_group_label>TV-46046 - 1</arm_group_label>
    <arm_group_label>TV-46046 - 2</arm_group_label>
    <arm_group_label>TV-46046 Placebo</arm_group_label>
    <arm_group_label>medroxyprogesterone acetate injectable suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has a low risk of pregnancy (ie, sterilized, in exclusively same-sex partnership, in
             menopause and/or post-menopausal, abstinent, in monogamous relationship with
             vasectomized partner, using nonhormonal intrauterine device (IUD) or consistent use of
             condoms)

          -  is not pregnant and does not have desire to become pregnant in the subsequent 18
             months

          -  had a normal mammogram within the last year, if 40 years or older

          -  has no skin disorders or skin allergies

               -  Additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  has hypertension

          -  has ischemic heart disease or a history of ischemic heart disease

          -  has a history of stroke

          -  has a history of thromboembolic event (s)

          -  has systemic lupus erythematosus

          -  has rheumatoid arthritis and is undergoing immunosuppressive therapy

          -  has migraine with aura

          -  has unexplained vaginal bleeding

          -  has diabetes

          -  has a strong family history of breast

          -  has cervical cancer or a history of cervical cancer

          -  has severe cirrhosis (decompensated) or liver tumors

          -  has known significant renal disease

          -  has a history of diagnosed clinical depression or bipolar disorder, with or without
             suicidal ideation, and/or history of suicide attempt

          -  is currently using hormonal contraception

          -  had an injection of DMPA (Depo-Provera CI or Depo-subQ 104) in the past 12 months; or
             combined injectable in the last 3 months

          -  is chronically using pain medication

          -  has a plan to move to another location in the next 18 months

               -  Additional criteria apply, please contact the investigator for more information
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Pharmaceuticals USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 1</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

